Information Provided By: 
Fly News Breaks for October 2, 2017
RGEN
Oct 2, 2017 | 06:52 EDT
First Analysis analyst Steven Schwartz upgraded Repligen to Overweight saying the recent selloff in shares is unwarranted. The analyst left the company's analyst day with more conviction in its ability to "remain at the front of the technology curve in its markets and capitalize on our projected 11-14% industry growth rates." Schwartz keeps a $47 price target for the shares.
News For RGEN From the Last 2 Days
There are no results for your query RGEN
